EP4196116
PHARMACEUTICAL COMPOSITION COMPRISING CABOZANTINIB, PLERIXAFOR, AFATINIB AND ETORICOXIB FOR USE IN THE TREATMENT OR PROPHYLAXIS OF NSCLC WITHOUT DRIVER MUTATIONS
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
12.8.2021EP published:
10.7.2024EP application number:
21766393.9
EPO information:
European Patent Register
Max expiry date:
11.8.2041
Title in English:
PHARMACEUTICAL COMPOSITION COMPRISING CABOZANTINIB, PLERIXAFOR, AFATINIB AND ETORICOXIB FOR USE IN THE TREATMENT OR PROPHYLAXIS OF NSCLC WITHOUT DRIVER MUTATIONSLanguage of the patent:
English
Timeline
Today
12.8.2021EP application
10.7.2024EP Publication
Owner
Name:
Langhammer, StefanAddress:
Hirschweg 8, 30938 Burgwedel, DE
Name:
EPO Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbHAddress:
Robert-Rössle-Str. 10 Haus 82, 13125 Berlin, DE
Inventor
Name:
HOFFMANN, JensAddress:
13125 Berlin, DE
Name:
GÜRGEN, DennisAddress:
13409 Berlin, DE
Name:
LANGHAMMER, STEFAN, Dr.Address:
30938 Burgwedel, DE
Priority
Number:
102020005002Date:
17.8.2020Country:
DE
Classification
Categories:
A61K 31/395, A61K 31/444, A61K 31/47, A61K 31/517, A61K 45/06, A61P 35/00